Minimal residual disease-negativity after treatment in DLBCL strongly correlates with remission and overall survival. However ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

Despite failing to achieve MRD-negativity after induction, patients with Ph+ acute lymphoblastic leukemia treated with ...